Valuation: Centessa Pharmaceuticals plc

Market Cap 626.66Cr 571.52Cr 528.42Cr 476.88Cr 898.13Cr 59TCr 933.54Cr 6.38TCr 2.52TCr 32TCr 2.35TCr 2.3TCr 1LCr P/E 2024
-8.13x
P/E 2025 -17.2x
Enterprise Value 609.04Cr 555.45Cr 513.56Cr 463.47Cr 872.87Cr 57TCr 907.29Cr 6.2TCr 2.45TCr 31TCr 2.28TCr 2.24TCr 97TCr EV / Sales 2024
-
EV / Sales 2025 23,18,10,355x
Free-Float
78.43%
Yield 2024 *
-
Yield 2025 -
1 day+0.80%
6 months+2.17%
Current year+61.94%
Current year 21.5
Extreme 21.5
40.56
1 year 21.5
Extreme 21.5
40.56
3 years 5.58
Extreme 5.583
40.56
5 years 2.88
Extreme 2.885
40.56
10 years 2.88
Extreme 2.885
40.56
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/10/2024
Chief Tech/Sci/R&D Officer 55 01/03/2023
Chief Administrative Officer 58 01/04/2021
Director TitleAgeSince
Director/Board Member - 24/06/2026
Director/Board Member - 24/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
24/06/26
Medicxi Ventures (Jersey) Ltd.
SellCompany -1,99,63,157 12.9020%
01/05/26 Tax

Chief Executive Officer

-604 0.0004%
26/03/26 Exercice

Executive/Senior Manager

71,994 0.0539%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%-.--%+42.81%+475.28% 626.65Cr
-1.34%-3.09%+56.10%+68.83% 6.55TCr
+0.59%-1.83%+8.98%+90.01% 5.89TCr
+0.54%+0.45%+25.96%+87.77% 5.52TCr
-2.34%-3.90%+10.90%+115.97% 4.61TCr
+0.09%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.56TCr
-1.76%-11.56%+126.44%+649.27% 3.46TCr
-0.17%-1.83%+82.46%+57.69% 3.25TCr
-1.69%-0.79%-40.58%+382.68% 2.63TCr
Average -0.79%-2.87%+35.03%+199.47% 4TCr
Weighted average by Cap. -0.81%-3.21%+34.31%+148.57%

Financials

2024 2025
Net sales - 15 13.68 12.65 11.41 21.5 1.4T 22.35 152.76 60.39 756.58 56.27 55.1 2.39T
Net income -24Cr -22Cr -20Cr -18Cr -34Cr -2.2TCr -35Cr -240.1Cr -95Cr -1.19TCr -88Cr -87Cr -3.75TCr -20Cr -18Cr -17Cr -15Cr -28Cr -1.85TCr -29Cr -201.17Cr -80Cr -996.32Cr -74Cr -73Cr -3.15TCr
Net Debt -36Cr -33Cr -31Cr -28Cr -52Cr -3.4TCr -54Cr -371.06Cr -146.68Cr -1.84TCr -136.69Cr -133.83Cr -5.8TCr -18Cr -16Cr -15Cr -13Cr -25Cr -1.65TCr -26Cr -179.44Cr -71Cr -888.72Cr -66Cr -65Cr -2.81TCr
Projected Income Statement - Annual - Centessa Pharmaceuticals plc
Logo Centessa Pharmaceuticals plc
Centessa Pharmaceuticals Limited, formerly Centessa Pharmaceuticals plc, is a clinical-stage pharmaceutical company, developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It has an early-stage immuno-oncology program focused on its LockBody technology platform. The OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1, NT2 and idiopathic hypersomnia. ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Employees
129
  1. Stock Market
  2. Stocks
  3. CNTA Stock